Morningstar

CVS Health Expands GLP-1 Support for Patients

Provided by Dow Jones

By Connor Hart 




  CVS Health will expand support for patients using GLP-1 medications, including lower-cost access programs, pharmacist support and over-the-counter products aimed at managing common side effects. 



  The company said Monday it will begin participating in the Centers for Medicare & Medicaid Services' Medicare GLP-1 Bridge program, effective July 1. The program will help address cost concerns, allowing eligible Medicare beneficiaries to obtain certain GLP-1 medications for $50 a month through Dec. 31, 2027. 



  For those not eligible for the program, CVS noted it accepts several third-party prescription discount cards, manufacturer coupons and manufacturer vouchers to help reduce out-of-pocket costs. 



  CVS will additionally launch a new digital health offering, a $49 virtual MinuteClinic visit that can connect eligible adults with licensed clinicians for weight-loss evaluations and, when appropriate, prescriptions for GLP-1 drugs. 



  The service will be available in 47 states and Washington, D.C., designed for adults between the ages of 18 and 64 who are overweight and intend to pay out-of-pocket for clinical weight-loss services. 





  Write to Connor Hart at connor.hart@wsj.com 





  (END) Dow Jones Newswires



  June 22, 2026 09:25 ET (13:25 GMT)


Copyright (c) 2026 Dow Jones & Company, Inc.
  

					The articles, information, and content displayed on this webpage may
					include materials prepared and provided by third parties. Such
					third-party content is offered for informational purposes only and
					is not endorsed, reviewed, or verified by Morningstar.
				
 

					Morningstar makes no representations or warranties regarding the
					accuracy, completeness, timeliness, or reliability of any third-party
					content displayed on this site. The views and opinions expressed in
					third-party content are those of the respective authors and do not
					necessarily reflect the views of Morningstar, its affiliates, or employees.
				
 

					Morningstar is not responsible for any errors, omissions, or delays
					in this content, nor for any actions taken in reliance thereon.
					Users are advised to exercise their own judgment and seek independent
					financial advice before making any decisions based on such content.
					The third-party providers of this content are not affiliated with
					Morningstar, and their inclusion on this site does not imply any
					form of partnership, agency, or endorsement.
				
 

				Popular
				
 
  
 
 
 
 
3 Stocks to Sell and 3 Stocks to Buy for October
 
Plus, lessons from September’s stock market activity. 
 
 
David Sekera, CFA and Susan Dziubinski 
 
 
 
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
 
With a 3.3% dividend yield and earnings growth expected to exceed management’s outlook, this 4-star stock stands out in a struggling sector. 
 
 
Andrew Bischof, CFA, CPA 
 
 
 
The Thrilling 37
 
Just a few strict screens can narrow the field to an elite group of funds. 
 
 
Russel Kinnel 
 
 
 
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
 
Ask the Analyst columnist Amy Arnott answers a grab bag of reader questions about bond ETFs, TIPS, retirement planning, and more. 
 
 
Amy C. Arnott, CFA and Ivanna Hampton 
 
 
 
3 Stocks to Invest In With More Room to Run
 
These stocks are up significantly in 2026, yet still look undervalued today. 
 
 
Susan Dziubinski 
 
 
 
 

			Sponsor Center